Advances in pathogenetic and clinical research of immune thrombocytopenic purpura
- VernacularTitle:免疫性血小板减少性紫癜的发病机制与临床研究进展
- Author:
Zhaoyue WANG
- Publication Type:Journal Article
- Keywords:
Immune thrombocytopenic purpura;
Pathogenesis;
Treatment;
Thrombopoietin;
Helicobacter pylori
- From:
Chinese Journal of Immunology
2009;25(12):1141-1144
- CountryChina
- Language:Chinese
-
Abstract:
Immune thrombocytopenic purpura (ITP) is characterized by autoantibody-mediated thrombocytopenia,with the major autoantigens being platelet glycoproteins.Cellular immunity is also involved in platelet destruction.ITP remains a diagnosis of exclusion,defined as primary and secondary ITP.The major goal for its treatment is to provide a safe platelet count.Corticosteroid-based regimens are commonly used as the initial treatment,and severe patients have temporary responses to intravenous immunoglobulin.Splenenectomy shows curative-potential in some chronic ITP cases.Thrombopoietic agents would become a new approach of treatment.Helicobacter pylori (H.pylori) infection should be screened in adult chronic ITP,and when the result is positive,H.pylori eradication therapy is indicated.
